Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POSIMIR vs ALCAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Single-dose administration in adults for local analgesia at the surgical site following bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty (TKA).
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 m L (66 mg) of the 1.32% solution.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
Terminal elimination half-life is approximately 27 hours (range 16-38 hours), supporting once-daily dosing in clinical use.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Primarily hepatic via conjugation with glucuronic acid; major metabolite is 4-hydroxybupivacaine. CYP3A4 and CYP1A2 are involved in minor oxidative metabolism.
Hydrolyzed by plasma esterases.
Primarily hepatic metabolism via CYP3A4 and CYP1A2 to inactive metabolites; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of total clearance.
Renal excretion of parent drug and metabolites: <5% unchanged.
Approximately 97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Minimal; <5% bound to plasma proteins.
Volume of distribution is approximately 1.9 L/kg, indicating extensive distribution into tissues.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Not applicable via oral route; only administered as a local infiltration. Systemic bioavailability after local administration is approximately 100% locally, but systemic levels are low due to slow release from the formulation.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
No dose adjustment is required for mild to moderate renal impairment. Safety and efficacy have not been established in severe renal impairment (GFR <30 m L/min), use with caution.
No dose adjustment required; negligible systemic absorption.
No dose adjustment is required for mild (Child-Pugh A) hepatic impairment. For moderate (Child-Pugh B) impairment, consider cautious use with monitoring for toxicity. Contraindicated in severe (Child-Pugh C) hepatic impairment.
No dose adjustment required; negligible systemic absorption.
Safety and efficacy in pediatric patients have not been established. No standard dosing guidelines exist.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
No specific dose adjustment is recommended, but elderly patients may have increased sensitivity and reduced clearance. Use with caution, monitoring for cardiac and neurological toxicity.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
Not approved for use in: obstetrical paravertebral block, epidural or intrathecal administration. Risk of cardiac arrest and death has been reported with bupivacaine use via these routes.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Risk of overdose and toxicity with unintentional intravascular injection or excessive dosing.,Do not use in patients with hypersensitivity to bupivacaine or any amide-type local anesthetic.,Not recommended for patients with severe hepatic impairment.,Safety in pediatric patients not established.,Use with caution in patients with cardiovascular disease, especially those with impaired cardiac conduction.,May cause methemoglobinemia in susceptible patients.,Chondrolysis with intra-articular use (not indicated for such use).
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Hypersensitivity to bupivacaine or any component of the formulation,Obstetrical paravertebral block,Epidural or intrathecal administration
Hypersensitivity to any component of the formulation.
No known food interactions. Avoid alcohol for 24 hours post-administration to minimize additive CNS depression.
None known.
POSIMIR (bupivacaine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but adequate human studies are lacking. First trimester: Risk of teratogenicity is unknown; bupivacaine crosses the placenta. Second and third trimesters: Potential for fetal bradycardia, CNS depression, and neurobehavioral effects. Use only if benefit outweighs risk.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Bupivacaine is excreted in breast milk in small amounts. The milk-to-plasma ratio (M/P) is approximately 0.3. The relative infant dose is estimated to be <2% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding, but caution is advised in infants with impaired hepatic function.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
No specific dose adjustments are recommended for POSIMIR in pregnancy. However, physiological changes (increased plasma volume, altered hepatic metabolism) may affect bupivacaine pharmacokinetics, potentially increasing systemic absorption. Use lowest effective dose and monitor for signs of toxicity.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
POSIMIR (bupivacaine) is a long-acting, non-opioid local analgesic administered via infiltration into the surgical site. Its liposomal bupivacaine formulation provides up to 72 hours of analgesia. Do not use for intra-articular, epidural, or intrathecal administration; risk of chondrolysis and nerve injury. Avoid concomitant use with other local anesthetics. Monitor for signs of systemic toxicity (e.g., CNS excitation, cardiac depression). Not recommended in patients with hepatic impairment or myasthenia gravis.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
POSIMIR is a long-acting anesthetic injected at the surgical site to reduce pain for up to 3 days.,Do not drive or operate machinery for at least 48 hours after administration due to potential dizziness or sedation.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Avoid applying heat or ice directly to the injection site unless advised by your surgeon.,You may still feel some sensation; use prescribed rescue analgesics as needed.,Do not use additional numbing creams or sprays near the surgical site.,Contact your doctor if you experience severe headache, blurred vision, or ringing in ears.,If you are pregnant or breastfeeding, discuss risks with your healthcare provider.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POSIMIR vs ALCAINE, answered by our medical review team.
POSIMIR is a Local Anesthetic that works by Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.. ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POSIMIR and ALCAINE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POSIMIR is: Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 m L (66 mg) of the 1.32% solution.. The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POSIMIR and ALCAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POSIMIR is classified as Category C. POSIMIR (bupivacaine) is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but adequate human studies are lacking. First trimester: Risk of teratogenici. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.